|Bid||16.80 x 800|
|Ask||16.84 x 1400|
|Day's Range||16.25 - 17.30|
|52 Week Range||0.20 - 22.49|
|Beta (5Y Monthly)||1.17|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 12, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.10|
By John Vandermosten, CFA NASDAQ:DRIO READ THE FULL DRIO RESEARCH REPORT DarioHealth (NASDAQ:DRIO) and HMC HealthWorks announced that they had entered into a sales and distribution partnership. HMC will incorporate DarioHealth’s digital therapeutics (DTx) platform into its comprehensive care management programs and offer DarioHealth’s platform as a stand-alone option. HMC HealthWorks is a
DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, and HMC HealthWorks, a 40-year veteran in healthcare management with clinically-integrated models of care that reduce healthcare costs and improve population health, today announced that the companies have entered into a sales and distribution partnership pursuant to which HMC will incorporate DarioHealth's digital therapeutics solution into its comprehensive care management programs. HMC will offer DarioHealth's platform on both a stand-alone basis as well as incorporated into HMC's comprehensive care management solutions.
DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announces that Eric Milledge has joined DarioHealth as Chairman of the company's newly-established Scientific Advisory Board (SAB).